Cantor Fitzgerald reiterated their overweight rating on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $140.00 price objective on the stock. Several other brokerages have also weighed in on NVO. Morgan Stanley started coverage on Novo Nordisk A/S in […]
Polen Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 7,906,255 shares of the company’s stock, valued at approximately $718,995,000. Novo Nordisk A/S accounts for about 1.9% of […]
Silverarc Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,000 shares of the company’s stock, valued at approximately $5,456,000. Novo Nordisk […]
Polen Capital Management LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,906,255 shares of the company’s stock, valued at approximately $718,995,000. Novo Nordisk A/S accounts for about 1.9% of Polen […]
Silverarc Capital Management LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 60,000 shares of the company’s stock, valued at approximately $5,456,000. Novo Nordisk A/S accounts for approximately […]